Synthetic lethal screens as a means to understand and treat MYC-driven cancers

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 3, 2014, Pages

  Cermelli, Silvia ^a   Jang, In Sock ^b   Bernard, Brady ^c   Grandori, Carla ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SAGE BIONETWORKS   (United States)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER GENOME; CANCER THERAPY; CELL CYCLE CHECKPOINT; CELL GROWTH; CELL METABOLISM; CSNK1E GENE; DEREGULATION; DEVELOPMENT; DNA REPAIR; DRUG TARGETING; GENE INTERACTION; GENOME; HUMAN; LETHALITY; MAX GENE; MYC SL GENE; NEOPLASM; NONHUMAN; ONCOGENE MYC; RNA INTERFERENCE; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; YEAST;

APOPTOSIS; CELL CYCLE; CELL ENLARGEMENT; DNA REPAIR; FORECASTING; GENES, LETHAL; GENES, MYC; GENES, TUMOR SUPPRESSOR; GENETIC THERAPY; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 84897583716     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014209     Document Type: Article

References (84)

1. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana H, Sheikh SS, et al. 2007. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 60: 768-772.
2. Amati B, Alevizopoulos K, Vlach J. 1998. Myc and the cell cycle. Front Biosci 3: D250-D268.
3. Badura L, Swanson T, Adamowicz W, Adams J, Cianfrogna J, Fisher K, Holland J, Kleiman R, Nelson F, Reynolds L, et al. 2007. An inhibitor of casein kinase I1 induces phase delays in circadian rhythms under free-running and entrained conditions. J Pharmacol Exp Ther 322: 730-738.
4. Bartkowiak B, Liu P, Phatnani HP, Fuda NJ, Cooper JJ, Price DH, Adelman K, Lis JT, Greenleaf AL. 2010. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev 24: 2303-2316.
5. Benanti JA, Galloway DA. 2004. Normal human fibroblasts are resistant to RAS-induced senescence. Mol Cell Biol 24: 2842-2852.
6. Benanti JA, Wang ML, Myers HE, Robinson KL, Grandori C, Galloway DA. 2007. Epigenetic down-regulation of ARF expression is a selection step in immortalization of human fibroblasts by c-Myc. Mol Cancer Res 5: 1181-1189.
7. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. 1992. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52: 1107-1113.
8. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, et al. 2007. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci 104: 20007-20012.
9. Blakely K, Ketela T, Moffat J. 2011. Pooled lentiviral shRNA screening for functional genomics in mammalian cells. Methods Mol Biol 781: 161-182.
10. Blancato J, Singh B, Liu A, Liao DJ, Dickson RB. 2004. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer 90: 1612-1619.
11. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. 2009. Triple negative breast cancer-Current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap MedFacUniv Palacky Olomouc Czech Repub 153: 13-17.
12. Bradner J. 2014. Inhibiting Myc. Cold Spring Harb Perspect Med doi:10.1101/cshperspect.a014266.
13. Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE. 2011. MK- 1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 17: 5638-5648.
14. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, Schleker T, Perna D, Tronnersjo S, Murga M, et al. 2009. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 12: 54-59.
15. Campbell KJ, White RJ. 2014.MYC regulation of cell growth through control of transcription by RNA polymerase I and III. Cold Spring Harb Perspect Med doi:10.1101/cshperspect.a018408.
16. Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N, Schultz N, Bader GD, Sander C. 2011. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res 39: D685-D690.
17. Chappell J, Dalton S. 2013. Roles for MYC in the establishment and maintenance of pluripotency. Cold Spring Harb Perspect Med 3: a014381.
18. Chung N, Locco L, Huff KW, Bartz S, Linsley PS, Ferrer M, Strulovici B. 2008. An efficient and fully automated highthroughput transfection method for genome-scale siRNA screens. J Biomol Screen 13: 142-148.
19. Conacci-Sorrell M, McFerrin L, Eisenman RN. 2014. An overview of MYC and its interactome. Cold Spring Harb Perspect Med 4: a014357.
20. Costanzo M, Baryshnikova A, VanderSluis B, Andrews B, Myers CL, Boone C. 2012. Genetic networks. In Handbook of systems biology-Concepts and insights (ed.Walhout M, et al.), pp. 115-136. Academic, San Diego.
21. Dang CV. 2013. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 3: a014217.
22. Darcy KM, Brady WE, Blancato JK, Dickson RB, Hoskins WJ, McGuire WP, Birrer MJ. 2009. Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecol Oncol 114: 472-479.
23. Dixon SJ, Costanzo M, Baryshnikova A, Andrews B, Boone C. 2009. Systematic mapping of genetic interaction networks. Ann Rev Genet 43: 601-625.
24. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R. 2007. Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-451.
25. Eilers M, Picard D, Yamamoto KR, Bishop JM. 1989. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 340: 66-68.
26. Evan G, Littlewood T. 1998. A matter of life and cell death. Science 281: 1317-1322.
27. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
28. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
29. Gallant P. 2013. Myc function in Drosophila. Cold Spring Harb Perspect Med 3: a014324.
30. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. 2007. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 13: 820-827.
31. Grandori C. 2013. A high throughput siRNA screening platform to identify MYC-synthetic lethal genes as candidate therapeutic targets. Methods Mol Biol 1012: 187-200.
32. Grandori C, Mac J, Siebelt F, Ayer DE, Eisenman RN. 1996. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo. EMBO J 15: 4344-4357.
33. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, White RJ. 2005. C- MYC BINDS to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 7: 311-318.
34. Gurley KE, Kemp CJ. 2001. Synthetic lethality between mutation in Atm andDNA-PKcs during murine embryogenesis. Curr Biol 11: 191-194.
35. Hann SR. 2014.Myc protein interactions. Cold Spring Harb Perspect Med doi:10.1101/cshperspect.a014399.
36. Hartwell LH, Szankasi P, Roberts CJ,Murray AW, Friend SH. 1997. Integrating genetic approaches into the discovery of anticancer drugs. Science 278: 1064-1068.
37. Holzel M, Grimm T, Rohrmoser M, Malamoussi A, Harasim T, Gruber-Eber A, Kremmer E, Eick D. 2007. The BRCT domain of mammalian Pes1 is crucial for nucleolar localization and rRNA processing. Nucleic Acids Res 35: 789-800.
38. Hu G, Kim J, Xu Q, Leng Y, Orkin SH, Elledge SJ. 2009. A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev 23: 837-848.
39. Hurlin PJ. 2013. Control of vertebrate development by MYC. Cold Spring Harb Perspect Med 3: a014332.
40. Hydbring P, Larsson LG. 2010. Tipping the balance: Cdk2 enables Myc to suppress senescence. Cancer Res 70: 6687-6691.
41. Johnston LA. 2014. Socializing with Myc: Cell competition in development and as a model for premalignant cancer. Cold Spring Harb Perspect Med doi:10.1101/cshperspect.a014274.
42. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, et al. 2012. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335: 348-353.
43. Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, Tibshirani R, Minna JD, Pollack JR. 2006. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 25: 130-138.
44. Kim SY, Dunn IF, Firestein R, Gupta P, Wardwell L, Repich K, Schinzel AC, Wittner B, Silver SJ, Root DE, et al. 2010. CK11 is required for breast cancers dependent on b-catenin activity. PLoS ONE 5: e8979.
45. Kuzyk A, Mai S. 2014. C-MYC-induced genomic instability. Cold Spring Harb Perspect Med doi: 10.1101/cshper spect.a014373.
46. Lee SW, Lee MH, Park JH, Kang SH, Yoo HM, Ka SH, Oh YM, Jeon YJ, Chung CH. 2012. SUMOylation of hnRNPK is required for p53-mediated cell-cycle arrest in response to DNA damage. EMBO J 31: 4441-4452.
47. Lin CJ, Nasr Z, Premsrirut PK, Porco JA Jr, Hippo Y, Lowe SW, Pelletier J. 2012. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep 1: 325-333.
48. Link JM, Ota S, Zhou ZQ, Daniel CJ, Sears RC, Hurlin PJ. 2012. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis. Proc Natl Acad Sci 109: 19685-19690.
49. Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR, Muthalagu N, Rycak L, Rudalska R, Moll R, et al. 2012. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 483: 608-612.
50. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. 2005. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: An issue of potency. Cancer Biol Ther 4: 934-936.
51. McMahon SB, Wood MA, Cole MD. 2000. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 20: 556-562.
52. Meng QJ, Logunova L, Maywood ES, Gallego M, Lebiecki J, Brown TM, Sladek M, Semikhodskii AS, Glossop NR, Piggins HD, et al. 2008. Setting clock speed in mammals: The CK1 1t mutation in mice accelerates circadian pacemakers by selectively destabilizing PERIOD proteins. Neuron 58: 78-88.
53. Morrish F, Hockenbery D. 2014. Myc and mitochondrial biogenesis. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014225.
54. Moser R, Toyoshima M, Robinson K, Gurley KE, Howie HL, Davison J, Morgan M, Kemp CJ, Grandori C. 2012.MYCdriven tumorigenesis is inhibited by WRN syndrome gene deficiency. Mol Cancer Res 10: 535-545.
55. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF, D'Artista L, Schleker T, Guerra C, Garcia E, et al. 2011. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 18: 1331-1335.
56. Nesbit CE, Tersak JM, Prochownik EV. 1999. MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016.
57. Nikiforov MA, Chandriani S, Park J, Kotenko I, Matheos D, Johnsson A, McMahon SB, Cole MD. 2002. TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins. Mol Cell Biol 22: 5054-5063.
58. O'Shea JM, Ayer DE. 2013. Coordination of nutrient availability and utilization by MAX- and MLX-centered transcription networks. Cold Spring Harb Perspect Med 3: a014258.
59. Paddison PJ, Silva JM, Conklin DS, Schlabach M, Li M, Aruleba S, Balija V, O'Shaughnessy A, Gnoj L, Scobie K, et al. 2004. A resource for large-scale RNA-interferencebased screens in mammals. Nature 428: 427-431.
60. Popov N, Herold S, Llamazares M, Schulein C, Eilers M. 2007. Fbw7 and Usp28 regulate Myc protein stability in response to DNA damage. Cell Cycle 6: 2327-2331.
61. Preuss F, Fan JY, Kalive M, Bao S, Schuenemann E, Bjes ES, Price JL. 2004. Drosophila doubletime mutations which either shorten or lengthen the period of circadian rhythms decrease the protein kinase activity of casein kinase I. Mol Cell Biol 24: 886-898.
62. Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE, et al. 2013. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential toMYC-dependent cancers. PLoSONE 8: e54873.
63. Rahl PB, Young RA. 2014. Myc and transcription elongation. Cold Spring Harb PerspectMed doi: 10.1101/cshper sect.a014340.
64. Robinson K, Asawachaicharn N, Galloway DA, Grandori C. 2009. c-Myc accelerates S-phase and requires WRN to avoid replication stress. PLoS ONE 4: e5951.
65. Rodriguez N, Yang J, Hasselblatt K, Liu S, Zhou Y, Rauh-Hain JA, Ng SK, Choi PW, Fong WP, Agar NY, et al. 2012. Casein kinase I1 interacts with mitochondrial proteins for the growth and survival of human ovarian cancer cells. EMBO Mol Med 4: 952-963.
66. Roussel MF, Robinson GW. 2013. Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med 3: a014308.
67. Sabò A, Amati B. 2014. Gemone recognition by Myc. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014191.
68. Sato H, Minei S, Hachiya T, Yoshida T, Takimoto Y. 2006. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients. Int J Urol 13: 761-766.
69. Sekine 2008. Yamaguchi T, Hamano K, YoungMW, Shimoda M, Saez L. Casein kinase I1 does not rescue doubletime function in Drosophila despite evolutionarily conserved roles in the circadian clock. 23: 3-15.
70. Simeonov A, Yasgar A, Jadhav A, Lokesh GL, Klumpp C, Michael S, Austin CP, Natarajan A, Inglese J. 2008. Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction. Anal Biochem 375: 60-70.
71. Sopko R, Huang D, Preston N, Chua G, Papp B, Kafadar K, Snyder M, Oliver SG, Cyert M, Hughes TR, et al. 2006. Mapping pathways and phenotypes by systematic gene overexpression. Mol Cell 21: 319-330.
72. Stumpf M, Wiuf C, eds. 2009. Statistical and evolutionary analysis of biological networks. Imperial College Press, London.
73. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, et al. 2012. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci 109: 9545-9550.
74. Vannini A, Cramer P. 2012. Conservation between the RNA polymerase I, II, and III transcription initiation machineries. Mol Cell 45: 439-446.
75. Varjosalo M, Bjorklund M, Cheng F, Syvanen H, Kivioja T, Kilpinen S, Sun Z, Kallioniemi O, Stunnenberg HG, He WW, et al. 2008. Application of active and kinase-deficient kinome collection for identification of kinases regulating Hedgehog signaling. Cell 133: 537-548.
76. Walton KM, Fisher K, Rubitski D, Marconi M, Meng QJ, Sladek M, Adams J, Bass M, Chandrasekaran R, Butler T, et al. 2009. Selective inhibition of casein kinase 11 minimally alters circadian clock period. J Pharmacol Exp Ther 330: 430-439.
77. Wang K, Saito M, Bisikirska BC, Alvarez MJ, Lim WK, Rajbhandari P, Shen Q, Nemenman I, Basso K, Margolin AA, et al. 2009. Genome-wide identification of posttranslational modulators of transcription factor activity in human B cells. Nat Biotechnol 27: 829-839.
78. Wang ML, Walsh R, Robinson KL, Burchard J, Bartz SR, Cleary M, Galloway DA, Grandori C. 2011. Gene expression signature of c-MYC-immortalized human fibroblasts reveals loss of growth inhibitory response to TGF-b. Cell Cycle 10: 2540-2548.
79. Welcker M, Orian A, Jin J, Grim JA, Harper JW, Eisenman RN, Clurman BE. 2004. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylationdependent c-Myc protein degradation. Proc Natl Acad Sci 101: 9085-9090.
80. Wiese K, Walz S, von Eyss B, Wolf E, Athineos D, Sansom O, Eilers M. 2013. The role of MIZ-1 in MYC-dependent tumorigenesis. Cold Spring Harb Perspect Med 4: a014290.
81. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. 2003. An integrated database of genes responsive to the Myc oncogenic transcription factor: Identification of direct genomic targets. Genome Biol 4: R69.
82. Zhang H, Fang Y, Huang C, Yang X, Ye Q. 2005. Human pescadillo induces large-scale chromatin unfolding. Sci China C Life Sci 48: 270-276.
83. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, Burchard J, Dai X, Chang AN, Diaz RL, et al. 2009. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8: 2756-2768.
84. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.